SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
PR Newswire
NEW YORK, March 27, 2024
NEW YORK, March 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company ("Bristol Myers" or the "Company") (NYSE: BMY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Bristol Myers and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On March 13, 2024, the U.S. Food and Drug Administration ("FDA") posted briefing documents in advance of meeting of the Oncologic Drugs Advisory Committee, scheduled for March 15, 2024, regarding Bristol Myers's CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial data submitted by Bristol Myers.
On this news, Bristol Myers's stock price fell $1.75 per share, or 3.22%, to close at $52.65 per share on March 13, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-bristol-myers-squibb-company---bmy-302101604.html
SOURCE Pomerantz LLP
-
What’s Happening In the Markets This Week
-
What Does Nvidia’s Stock Split Mean for Investors?
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Best- and Worst-Performing Stocks of May 2024
-
3 Stocks to Buy and 3 Stocks to Sell in June
-
Markets Brief: Friday’s Job Report in Focus
-
These Stocks Are (Still) Powering the Bull Market
-
Nio Earnings: Revenue and Loss Largely In Line, but Vehicle Margin Missed Amid Price Competition
-
The Best Biotech Stocks to Buy
-
After Earnings, Is Marvell Stock a Buy, a Sell, or Fairly Valued?
-
Nvidia Raised Its Dividend — but There’s a Catch
-
Lululemon Earnings: On Track to Meet Expectations Despite Slowdown In Americas
-
What Is Driving Small-Cap Stock Underperformance?
-
After Earnings, Is Zscaler Stock a Buy, a Sell, or Fairly Valued?
-
ASML Fair Value Raised as Outlook Improves